Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy
Tovorafenib demonstrated single-agent clinical activity in solid tumors with BRAF fusions or CRAF fusions or amplification and had a manageable safety profile and may offer a new targeted treatment option for adult patients with tumors harboring these rare genomic driver alterations.